Cannabis and COVID conversations during the pandemic, featuring the UCLA Cannabis Research Initiative Steering Committee, Donald Tashkin, M.D., Timothy Fong, M.D., and Ziva Cooper, Ph.D.
The anecdotal evidence that cannabis has a positive effect on a long list of medical conditions is building. At long last, researchers are now applying scientific rigor to convert anecdote into data that is showing great promise.
Sara Jane Ward, PhD, Assistant Professor of Pharmacology at Temple University's Lewis Katz School of Medicine, discusses the general classifications of cannabinoids and their potential therapeutic benefits.
From swollen joints to dementia, seniors are increasingly looking to cannabis to treat the ailments of aging, and a study is underway to better understand its effectiveness. The goal of this research is to offer an improved quality of life, but to also gather data on the effects of cannabidiol (CBD) on a range of factors that affect our aging population. Pain management, agitation with dementia, and ability to sleep are all being studied.
Cannabis and Cannabinoids: A Neuroscience Research Summit, convened by the National Institutes of Health (NIH), focused on the neurological and psychiatric effects of cannabis, other cannabinoids, and the endocannabinoid system. Both the adverse and the potential therapeutic effects of the cannabinoid system were discussed. The goal of the summit was to ensure evidence-based information to inform practice and policy, particularly important given the rapidly shifting landscape regarding the recreational and medicinal use of cannabis.
This two day summit was sponsored by several NIH Institutes and Centers: the National Institute on Drug Abuse (NIDA); the National Institute on Alcohol Abuse and Alcoholism (NIAAA); the National Center for Complementary and Integrative Health (NCCIH); the National Institute of Mental Health (NIMH); and the National Institute of Neurological Disorders and Stroke (NINDS).
🎥 DAY 1: https://videocast.nih.gov/summary.asp?Live=18464&bhcp=1
Donald Abrams, MD, was Chief of the Hematology-Oncology Division at Zuckerberg San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. In addition, he has an Integrative Oncology consultation practice at the UCSF Osher Center for Integrative Medicine. Dr. Abrams received an AB in Molecular Biology from Brown University in 1972 and graduated from the Stanford University School of Medicine in 1977.
Professor Raphael Mechoulam, PhD is an organic chemist and President of the Multidisciplinary Center For Cannabinoid Research at The Hebrew University in Jerusalem. He is best known for his work in the isolation, structure elucidation and total synthesis of Delta-9-THC. In this video, Mechoulam discusses the chemistry of cannabinoid acids and the technology he developed to stabilize them.
Dr. Jon Ebbert, MD, an addiction specialist at Mayo Clinic, explains how medical cannabis is used to treat pain and disease symptoms.
An observational study of patients over the age of 65 reveals encouraging data. After six months of treatment, median pain scores were reduced 50%. Prior to treatment, a Quality of Life assessment indicated that approximately two-thirds of patients defined their quality as very bad. After treatment, only 16% defined their quality of life as such. Furthermore, some patients were able to reduce their use of opioids, benzodiazepenes and other pharmaceuticals.
For patients managing arthritis pain, cannabis has offered relief. In a disease with a 5.5 inflammation factor, medical cannabis reduced the factor to 2.0; whereas using conventional medication, the factor was only reduced to 3.0.
David Casarett, MD, Professor of Medicine at Duke University and Chief of Palliative Care at Duke Health, was tired of hearing hype and half-truths around medical cannabis, so he put on his skeptic's hat and investigated on his own. He shares a fascinating report on what we know and what we don't -- and what mainstream medicine could learn from the modern medical cannabis dispensary.
Staci Gruber, PhD, Associate Professor of Psychiatry at Harvard Medical School, addresses Congress about the importance of allowing cannabis research.
The case of Cannabinoid Hyperemesis Syndrome (CHS) shares two stories; one of Alice Moon and her journey to discovering that she suffers from CHS and the other of Dr. Andrew Meltzer, an emergency room physician at The George Washington University who treats patients with Cannabis Hyperemesis Syndrome.